Anti‐TIF1γ antibody‐positive dermatomyositis associated with durvalumab administration in a patient with lung and oesophageal cancers

We report a case of anti‐transcriptional intermediary factor 1γ (TIF1γ) antibody‐positive dermatomyositis following durvalumab treatment. The patient was successfully treated with pulse steroid therapy, high‐dose intravenous immunoglobulin (IVIg), and tacrolimus. Durvalumab may induce dermatomyositi...

Descripción completa

Detalles Bibliográficos
Autores principales: Imai, Ryosuke, Ikemura, Sumie, Jinta, Torahiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Ltd 2021
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7985661/
https://www.ncbi.nlm.nih.gov/pubmed/33777398
http://dx.doi.org/10.1002/rcr2.736
_version_ 1783668294454083584
author Imai, Ryosuke
Ikemura, Sumie
Jinta, Torahiko
author_facet Imai, Ryosuke
Ikemura, Sumie
Jinta, Torahiko
author_sort Imai, Ryosuke
collection PubMed
description We report a case of anti‐transcriptional intermediary factor 1γ (TIF1γ) antibody‐positive dermatomyositis following durvalumab treatment. The patient was successfully treated with pulse steroid therapy, high‐dose intravenous immunoglobulin (IVIg), and tacrolimus. Durvalumab may induce dermatomyositis, and early diagnosis and aggressive therapy are crucial to prevent severe dermatomyositis, which is potentially treatable.
format Online
Article
Text
id pubmed-7985661
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley & Sons, Ltd
record_format MEDLINE/PubMed
spelling pubmed-79856612021-03-25 Anti‐TIF1γ antibody‐positive dermatomyositis associated with durvalumab administration in a patient with lung and oesophageal cancers Imai, Ryosuke Ikemura, Sumie Jinta, Torahiko Respirol Case Rep Case Reports We report a case of anti‐transcriptional intermediary factor 1γ (TIF1γ) antibody‐positive dermatomyositis following durvalumab treatment. The patient was successfully treated with pulse steroid therapy, high‐dose intravenous immunoglobulin (IVIg), and tacrolimus. Durvalumab may induce dermatomyositis, and early diagnosis and aggressive therapy are crucial to prevent severe dermatomyositis, which is potentially treatable. John Wiley & Sons, Ltd 2021-03-23 /pmc/articles/PMC7985661/ /pubmed/33777398 http://dx.doi.org/10.1002/rcr2.736 Text en © 2021 The Authors. Respirology Case Reports published by John Wiley & Sons Australia, Ltd on behalf of The Asian Pacific Society of Respirology. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Reports
Imai, Ryosuke
Ikemura, Sumie
Jinta, Torahiko
Anti‐TIF1γ antibody‐positive dermatomyositis associated with durvalumab administration in a patient with lung and oesophageal cancers
title Anti‐TIF1γ antibody‐positive dermatomyositis associated with durvalumab administration in a patient with lung and oesophageal cancers
title_full Anti‐TIF1γ antibody‐positive dermatomyositis associated with durvalumab administration in a patient with lung and oesophageal cancers
title_fullStr Anti‐TIF1γ antibody‐positive dermatomyositis associated with durvalumab administration in a patient with lung and oesophageal cancers
title_full_unstemmed Anti‐TIF1γ antibody‐positive dermatomyositis associated with durvalumab administration in a patient with lung and oesophageal cancers
title_short Anti‐TIF1γ antibody‐positive dermatomyositis associated with durvalumab administration in a patient with lung and oesophageal cancers
title_sort anti‐tif1γ antibody‐positive dermatomyositis associated with durvalumab administration in a patient with lung and oesophageal cancers
topic Case Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7985661/
https://www.ncbi.nlm.nih.gov/pubmed/33777398
http://dx.doi.org/10.1002/rcr2.736
work_keys_str_mv AT imairyosuke antitif1gantibodypositivedermatomyositisassociatedwithdurvalumabadministrationinapatientwithlungandoesophagealcancers
AT ikemurasumie antitif1gantibodypositivedermatomyositisassociatedwithdurvalumabadministrationinapatientwithlungandoesophagealcancers
AT jintatorahiko antitif1gantibodypositivedermatomyositisassociatedwithdurvalumabadministrationinapatientwithlungandoesophagealcancers

Ejemplares similares